Acquisitions (Tables)

12 Months Ended

Dec. 31, 2012

AmniSure [Member]

As of December 31, 2012, the final purchase price allocation is as follows:



(in thousands)	AmniSure acquisition
Purchase price:
Cash consideration	$	101,415
Fair value of contingent consideration	4,530
	$	105,945

Allocation:
Working capital	$	5,297
Fixed and other long-term assets	267
Developed technology, licenses and know-how	28,941
Customer relationships	25,520
Tradenames	2,692
In-process research and development	4,522
Goodwill	44,369
Deferred tax liability on fair value of identifiable intangible assets acquired	(5,202		)
Long-term liabilities assumed	(461		)
	$	105,945

Cellestis [Member]

As of December 31, 2012, the final purchase price allocation for Cellestis is as follows:



(in thousands)	Cellestis acquisition
Purchase price:
Cash consideration paid	$	372,452
	$	372,452

Allocation:
Working capital	$	18,465
Fixed and other long-term assets	1,112
Developed technology, licenses and know-how	67,500
Customer relationships	48,800
Tradenames	12,000
Goodwill	258,886
Deferred tax liability on fair value of identifiable intangible assets acquired	(34,079		)
Liabilities assumed	(232		)
	$	372,452

Ipsogen [Member]

As of December 31, 2012, the final purchase price allocation is as follows:



(in thousands)	Ipsogen acquisition
Purchase price:
Cash consideration paid	$	57,436
Fair value of remaining shares	42,437
	$	99,873

Allocation:
Working capital	$	15,284
Deferred tax asset of acquired NOLs	8,997
Fixed and other long-term assets	2,429
Developed technology, licenses and know-how	44,500
Customer relationships	11,000
Tradenames	1,400
Goodwill	37,500
Deferred tax liability on fair value of identifiable intangible assets acquired	(19,325		)
Liabilities assumed	(1,912		)
	$	99,873